

Sandip Basu Dnb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/769150/publications.pdf>

Version: 2024-02-01

205
papers

1,948
citations

304368

22
h-index

395343

33
g-index

206
all docs

206
docs citations

206
times ranked

2128
citing authors

#	ARTICLE	IF	CITATIONS
1	Quality of life comparison in thyroxine hormone withdrawal versus triiodothyronine supplementation prior to radioiodine ablation in differentiated thyroid carcinoma: a prospective cohort study in the Indian population. <i>European Archives of Oto-Rhino-Laryngology</i> , 2022, 279, 2011-2018.	0.8	4
2	False positive ⁶⁸ Ga-DOTATATE PET-CT in Hereditary hypophosphatemic-osteomalacia mimicking culprit lesions of tumor induced osteomalacia. <i>Journal of Nuclear Medicine Technology</i> , 2022, , jnmt.121.263776.	0.4	1
3	Estimation of Absorbed Doses of Indigenously Produced ¹⁷⁷ Lu-DOTA-TATE PRRT in Normal Organs and Tumor Lesions in Patients of Metastatic Neuroendocrine Tumors: Comparison with No-Carrier-Added [¹⁷⁷ Lu]Lu-DOTA-TATE and the Trend with Multiple Cycles. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2022, 37, 214-225.	0.7	1
4	Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of ¹⁷⁷ Lu-DOTATATE PRRT: Does In Vivo Molecular PET Perform Better from the Viewpoint of Prediction of Tumor Biology?. <i>Journal of Nuclear Medicine Technology</i> , 2022, 50, 248-255.	0.4	3
5	Dynamic PET in prostate cancer: basic concepts and potential applications. <i>Clinical and Translational Imaging</i> , 2022, 10, 243-248.	1.1	0
6	The efficacy, toxicity and survival of salvage retreatment PRRT with ¹⁷⁷ Lu-DOTATATE in patients with progressive NET following initial course of PRRT. <i>British Journal of Radiology</i> , 2022, 95, .	1.0	6
7	Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant ¹⁸ F Uptake. <i>Neuroendocrinology</i> , 2021, 111, 998-1004.	1.2	19
8	Examining Absorbed Doses of Indigenously Developed ¹⁷⁷ Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 292-304.	0.7	12
9	¹³¹ I-MIBG negative progressive symptomatic metastatic paraganglioma: response and outcome with ¹⁷⁷ Lu-DOTATATE peptide receptor radionuclide therapy. <i>Annals of Nuclear Medicine</i> , 2021, 35, 92-101.	1.2	14
10	Long-term outcome of indigenous ¹⁷⁷ Lu-DOTATATE PRRT in patients with Metastatic Advanced Neuroendocrine Tumours: a single institutional observation in a large tertiary care setting. <i>British Journal of Radiology</i> , 2021, 94, 20201041.	1.0	19
11	Long-term outcome of ¹⁷⁷ Lu-DOTATATE-chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 913-923.	3.3	24
12	Initial clinical evaluation of indigenous ⁹⁰ Y-DOTATATE in sequential duo-PRRT approach (¹⁷⁷ Lu-DOTATATE and ⁹⁰ Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability, ⁹⁰ Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects. <i>World Journal of Nuclear Medicine</i> , 2021, 20, 73-81.	0.3	5
13	Clinical efficacy of Sep-Pak [®] assisted one pot automated synthesis of pharmaceutical grade [¹⁸ F]FLT using 5- ² -O-(benzoyl)-2,3- ² -anhydrothymidine precursor. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2021, 327, 585-596.	0.7	0
14	Follicular thyroid carcinoma metastasizing to rare sites and exhibiting variable inter-lesional heterogeneity on ¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography and ¹³¹ I. <i>World Journal of Nuclear Medicine</i> , 2021, 20, 312.	0.3	1
15	Grade 3 metastatic neuroendocrine neoplasms of two unusual primary sites with contrasting differentiation characteristics: Dual tracer positron emission tomography and computed tomography imaging (¹⁸ F-fluorodeoxyglucose and ⁶⁸ Ga-DOTATATE) correlates and their treatment implications. <i>World Journal of Nuclear Medicine</i> . 2021, 20, 125.	0.3	2
16	Concept proposal for a six-tier integrated dual tracer PET-CT (⁶⁸ Ga-PSMA and FDG) image scoring system (¹⁸ F-Pro-PET [™] score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis. <i>Nuclear Medicine Communications</i> , 2021, 42, 566-574.	0.5	7
17	Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant ¹⁷⁷ Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1558-1563.	2.8	26
18	High-Specific-Activity- ¹³¹ I-MIBG versus ¹⁷⁷ Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2021, 27, 2989-2995.	3.2	42

#	ARTICLE	IF	CITATIONS
19	On the Separation of Yttrium-90 from High-Level Liquid Waste: Purification to Clinical-Grade Radiochemical Precursor, Clinical Translation in Formulation of 90Y-DOTATATE Patient Dose. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 143-159.	0.7	2
20	Correlation of Lesional Uptake Parameters and Ratios with miPSMA Score and Estimating Normal Physiologic Concentration: An Exploratory Analysis in Metastatic Castration-Resistant Prostatic Carcinoma Patients with ⁶⁸ Ga-PSMA-11 PET/CT. <i>Journal of Nuclear Medicine Technology</i> , 2021, 49, 235-240.	0.4	3
21	Therapeutic Multidose Preparation of a Ready-to-Use ¹⁷⁷ Lu-PSMA-617 Using Carrier Added Lutetium-177 in a Hospital Radiopharmacy and Its Clinical Efficacy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 682-692.	0.7	2
22	Combined ¹⁷⁷ Lu-PSMA-617 PRLT and abiraterone acetate versus ¹⁷⁷ Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: An observational study comparing the response and durability. <i>Prostate</i> , 2021, 81, 1225-1234.	1.2	11
23	Poorly Differentiated Neuroendocrine Carcinoma of the Parotid Gland and Moderately Differentiated Hepatic Metastases: A Discordant Histopathology Clarified by Dual-Tracer PET/CT. <i>Journal of Nuclear Medicine Technology</i> , 2021, 49, 86-88.	0.4	2
24	Differential tumor biology between locoregional and distant metastasis in a patient with TENIS with TKI-resistant aggressive recurrent disease: a comparative evaluation with FDG, ⁶⁸ Ga-DOTATATE and ⁶⁸ Ga-PSMA-11 PET-CT. <i>Journal of Nuclear Medicine Technology</i> , 2021, , jnmt.121.263452.	0.4	0
25	Large cardiac metastasis from pancreatic neuroendocrine tumor and response to peptide receptor radionuclide therapy with ¹⁷⁷ Lu-DOTATATE. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 340-341.	1.4	1
26	Availability of both [¹⁷⁷ Lu]Lu-DOTA-TATE and [⁹⁰ Y]Y-DOTATATE as PRRT agents for neuroendocrine tumors: can we evolve a rational sequential duo-PRRT protocol for large volume resistant tumors?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 756-758.	3.3	12
27	Rare-Site Primary Soft-Tissue Neuroendocrine Tumor with Metastases and Near-Complete Resolution with ¹⁷⁷ Lu-DOTATATE: Documenting a Promising Clinical Application of Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine Technology</i> , 2020, 48, 36-39.	0.4	2
28	PET/Computed Tomography in Treatment Response Assessment in Cancer. <i>PET Clinics</i> , 2020, 15, 101-123.	1.5	8
29	Clinical utility of ¹⁷⁷ Lu-DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity. <i>Head and Neck</i> , 2020, 42, 401-416.	0.9	50
30	Towards personalizing treatment strategies in mCRPC: can dual-tracer PET-CT provide insights into tumor biology, guide the optimal treatment sequence, and individualize decision-making (between Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 disease course?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1793-1797.	3.3	5
31	Sequential Duo-“Peptide Receptor Radionuclide Therapy With Indigenous ⁹⁰ Y-DOTATATE and ¹⁷⁷ Lu-DOTATATE in Large-Volume Neuroendocrine Tumors. <i>Clinical Nuclear Medicine</i> , 2020, 45, 714-715.	0.7	3
32	Occurrence of the Redifferentiation-Akin Phenomenon on ⁶⁸ Ga-DOTATATE PET/CT After CAPTEM Chemotherapy in Metastatic Neuroendocrine Tumors with Intermediate MIB1 Index: What Could Be the Molecular Explanation?. <i>Journal of Nuclear Medicine Technology</i> , 2020, 48, 290-291.	0.4	3
33	Combined ¹⁷⁷ Lu-DOTATATE Peptide Receptor Radionuclide Therapy and Platinum-Based Chemotherapy in Recurrent, Metastatic Sinonasal Neuroendocrine Carcinoma: A Promising Therapeutic Option. <i>Journal of Nuclear Medicine Technology</i> , 2020, 48, 292-294.	0.4	7
34	Comparison of Dual-Tracer PET and CT Features to Conventional Risk Categories in Assessing Response to ¹⁷⁷ Lu-PSMA-617 Therapy for Metastatic Prostate Adenocarcinoma with Urinary Bladder Involvement. <i>Journal of Nuclear Medicine Technology</i> , 2020, 48, 148-153.	0.4	4
35	Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 447-464.	2.5	30
36	PET/Computed Tomography in Pulmonary and Thoracic Inflammatory Diseases (Including Cardiac) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.5	3

#	ARTICLE	IF	CITATIONS
37	Clinical efficacy of ¹⁷⁷ Lu-DOTATATE peptide receptor radionuclide therapy in thyroglobulin-elevated negative iodine scintigraphy: A "not-so-promising" result compared to GEP-NETs. World Journal of Nuclear Medicine, 2020, 19, 205-210.	0.3	7
38	Case work-up and monitoring of systemic radionuclide therapies: A proposed 3-sheet excel format with integrated graph for implementation in a busy treatment set-up. World Journal of Nuclear Medicine, 2020, 19, 447.	0.3	0
39	Interpreting discordance on dual-tracer positron emission tomography/computed tomography in the setting of metastatic neuroendocrine tumor: Detection of metachronous triple-negative breast carcinoma. World Journal of Nuclear Medicine, 2020, 19, 414-416.	0.3	2
40	"Tumour sink effect" on the diagnostic or posttreatment radioiodine scan due to sequestration into large-volume functioning metastasis of differentiated thyroid carcinoma influencing uptake in smaller metastatic sites or remnant thyroid tissue: An uncommon but possible phenomenon in thyroid cancer practice. World Journal of Nuclear Medicine, 2020, 19, 141-143.	0.3	2
41	Indian Council of Medical Research Consensus Document for the Management of Gastroenteropancreatic Neuroendocrine Neoplasms. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 166-172.	0.1	1
42	One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [¹⁷⁷ Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting. American Journal of Nuclear Medicine and Molecular Imaging, 2020, 10, 178-211.	1.0	3
43	Multiple Adhesions Diagnosed on ^{99m} Tc-Nanocolloid Peritoneal Scintigraphy in a Patient with Previous Continuous Ambulatory Peritoneal Dialysis (CAPD). Journal of the Association of Physicians of India, The, 2020, 68, 63.	0.0	0
44	Small Cell Transformation of Metastatic Prostate Adenocarcinoma Diagnosed by Dual-Tracer PET/CT (⁶⁸ Ga-PSMA and ¹⁸ F-FDG): Potential Clinical Utility in Therapeutic Decision Making and Treatment Monitoring. Journal of Nuclear Medicine Technology, 2019, 47, 85-87.	0.4	8
45	Bilateral Orbital Soft-Tissue Metastases from Renal Neuroendocrine Tumor: Successful Theranostic Application of ⁶⁸ Ga/ ¹⁷⁷ Lu-DOTATATE with Improvement of Vision. Journal of Nuclear Medicine Technology, 2019, 47, 171-172.	0.4	6
46	Therapeutic efficacy, prognostic variables and clinical outcome of ¹⁷⁷ Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort. British Journal of Radiology, 2019, 92, 20190380.	1.0	44
47	Metastatic or locally advanced mediastinal neuroendocrine tumours. Nuclear Medicine Communications, 2019, 40, 947-957.	0.5	8
48	Well-differentiated grade 3 neuroendocrine tumours and poorly differentiated grade 3 neuroendocrine carcinomas. Nuclear Medicine Communications, 2019, 40, 1086-1087.	0.5	10
49	In Vivo Molecular Imaging of Musculoskeletal Inflammation and Infection. PET Clinics, 2019, 14, 43-59.	1.5	5
50	Findings for Differentiated Thyroid Carcinoma by ¹³¹ I-Camera-Based and Uptake-Probe-Based Methods in Comparison with Diagnostic Radioiodine Scanning. Journal of Nuclear Medicine Technology, 2019, 47, 238-242.	0.4	1
51	Biodistribution and Dosimetry of Indigenously Produced ¹³¹ I-Rituximab in B-Cell Lymphoma: Pilot Study Estimating Patient-Specific Dose Comparing 2 Different Dosimetric Methods. Journal of Nuclear Medicine Technology, 2019, 47, 292-299.	0.4	0
52	Prevalence of hitherto unknown brain meningioma detected on ⁶⁸ Ga-DOTATATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of ¹⁷⁷ Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors. World Journal of Nuclear Medicine, 2019, 18, 160-170.	0.3	25
53	Implications of fluorodeoxyglucose uptake in low-intermediate grade metastatic neuroendocrine tumors from peptide receptor radionuclide therapy outcome viewpoint: A semi-quantitative standardized uptake value-based analysis. World Journal of Nuclear Medicine, 2019, 18, 389-395.	0.3	8
54	Metastatic large cell neuroendocrine carcinoma of larynx: Individualizing tumor biology by dual tracer positron emission tomography/computed tomography (⁶⁸ Ga-DOTATATE) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67 Td (and18F-fluoride) peptide receptor radionuclide therapy after initial progression on chemoradiotherapy. World Journal of Nuclear Medicine, 2019, 18, 431.	0.3	1

#	ARTICLE	IF	CITATIONS
55	Evaluating cardiac hypoxia in hibernating myocardium: Comparison of ^{99m} Tc-MIBI/ ¹⁸ F-fluorodeoxyglucose and ¹⁸ F-fluoromisonidazole positron emission tomography-computed tomography in relation to normal, hibernating, and infarct myocardium. <i>World Journal of Nuclear Medicine</i> , 2019, 18, 30.	0.3	2
56	Leveraging the power of non-radium radionuclide treatments in bone metastases. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 159-169.	0.4	0
57	Non- ¹⁸ F- ¹⁸ F-Fluoro-2-Deoxy- d -Glucose PET/Computed Tomography in Gynecologic Oncology. <i>PET Clinics</i> , 2018, 13, 239-248.	1.5	1
58	Neoadjuvant strategies for advanced pancreatic neuroendocrine tumors. <i>Nuclear Medicine Communications</i> , 2018, 39, 94-95.	0.5	6
59	The rationality of combining second-generation antiandrogens with ¹⁷⁷ Lu-PSMA or its alpha-emitting congeners for better and durable results. <i>Nuclear Medicine Communications</i> , 2018, 39, 1061-1063.	0.5	4
60	PET/Computed Tomography and PET/MR Imaging. <i>PET Clinics</i> , 2018, 13, 459-476.	1.5	4
61	Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors. <i>Nuclear Medicine Communications</i> , 2018, 39, 1143-1149.	0.5	14
62	Peptide Receptor Radionuclide Therapy with ¹⁷⁷ Lu-DOTATATE in Carcinoid Heart Disease: A Contraindication or a Promising Treatment Approach Bettering Chances for Corrective Surgery?. <i>Journal of Nuclear Medicine Technology</i> , 2018, 46, 292-294.	0.4	5
63	Surgical outcomes of thyroid cancer patients in a tertiary cancer center in India. <i>Indian Journal of Cancer</i> , 2018, 55, 23.	0.2	9
64	¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of unknown primary: A subgroup-specific analysis based on clinical presentation. <i>World Journal of Nuclear Medicine</i> , 2018, 17, 219.	0.3	4
65	¹⁷⁷ Lu-DOTATATE peptide receptor radionuclide therapy in patients with borderline low and discordant renal parameters: Treatment feasibility assessment by sequential estimation of triple parameters and filtration fraction. <i>World Journal of Nuclear Medicine</i> , 2018, 17, 12.	0.3	3
66	Solitary metacarpophalangeal metastasis from poorly differentiated thyroid carcinoma: Excellent tumor marker and scan response to two fractions of radioiodine therapy. <i>Indian Journal of Nuclear Medicine</i> , 2018, 33, 362.	0.1	0
67	Discordant Primary Resistance to Imatinib Mesylate in the Same Individual and Splenic Involvement in Recurring Gastric Gastrointestinal Stromal Tumors: Assessment by Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography. <i>Indian Journal of Nuclear Medicine</i> , 2018, 33, 140.	0.1	0
68	Individualized management of pyrexia of unknown origin: Will fludeoxyglucose-positron emission tomography/computed tomography emerge as the imaging common-point in the algorithm?. <i>Indian Journal of Nuclear Medicine</i> , 2018, 33, 376.	0.1	1
69	Thyroglobulin "Nonsecretor" Metastatic Poorly Differentiated Thyroid Carcinoma with Noniodine Concentrating Disease and Aggressive Clinical Course: A Clinical Case Series. <i>Indian Journal of Nuclear Medicine</i> , 2018, 33, 218-223.	0.1	0
70	MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with ⁶⁸ Ga-DOTATATE and ¹⁸ F-FDG and Multimodality Anatomic Imaging in Metastatic Neuroendocrine Tumors of Unknown Primary in a PRRT Workup Setting. <i>Journal of Nuclear Medicine Technology</i> , 2017, 45, 34-41.	0.4	27
71	Monitoring metastatic lesions in TENIS, initiating multi-targeted tyrosine kinase inhibitors and follow-up: should the newer FDG PET-CT quantitative indices be the defining objective parameter in clinical trials?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1092-1094.	3.3	2
72	Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with ¹⁷⁷ Lu-DOTATATE. <i>Clinical Nuclear Medicine</i> , 2017, 42, 428-435.	0.7	45

#	ARTICLE	IF	CITATIONS
73	Envisaging an alpha therapy programme in the atomic energy establishments: the priorities and the nuances. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1244-1246.	3.3	1
74	Mucoepidermoid Parotid Gland Tumor Found on Follow-up Radioiodine Scan for Differentiated Papillary Thyroid Cancer. <i>Journal of Nuclear Medicine Technology</i> , 2017, 45, 116-118.	0.4	1
75	Dual time point 18 F-FDG-PET and PET/CT for Differentiating Benign From Malignant Musculoskeletal Lesions: Opportunities and Limitations. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 373-391.	2.5	49
76	Developing a dedicated comprehensive ^{177}Lu -radionuclide therapy program. <i>Nuclear Medicine Communications</i> , 2017, 38, 103-105.	0.5	2
77	Designing and Developing PET-Based Precision Model in Thyroid Carcinoma. <i>PET Clinics</i> , 2017, 12, 27-37.	1.5	3
78	Response to. <i>Nuclear Medicine Communications</i> , 2017, 38, 1133-1134.	0.5	0
79	Volumetric high-resolution computed tomography in evaluating pulmonary metastases from differentiated thyroid carcinoma. <i>Nuclear Medicine Communications</i> , 2017, 38, 881-882.	0.5	1
80	Short course of oral lithium therapy as an adjunct in patients with thyrotoxicosis who failed initial radioiodine therapy. <i>Nuclear Medicine Communications</i> , 2017, 38, 726-727.	0.5	3
81	Dual tracer pet imaging (68ga-dotatate and 18f-fdg) features in pulmonary carcinoid: Correlation with tumor proliferation index. <i>Indian Journal of Nuclear Medicine</i> , 2017, 32, 39.	0.1	5
82	Metabolic bone disease in the context of metastatic neuroendocrine tumor: differentiation from skeletal metastasis, the molecular PET-CT imaging features, and exploring the possible etiopathologies including parathyroid adenoma (MEN1) and paraneoplastic humoral hypercalcemia of malignancy due to PTHrP hypersecretion. <i>World Journal of Nuclear Medicine</i> , 2017, 16, 62-67.	0.3	5
83	Peptide receptor radionuclide therapy with ^{177}Lu -DOTATATE for metastatic neuroendocrine tumor occurring in association with multiple endocrine neoplasia type 1 and cushing's syndrome. <i>World Journal of Nuclear Medicine</i> , 2017, 16, 126-132.	0.3	8
84	^{177}Lu -DOTATATE peptide receptor radionuclide therapy in metastatic or advanced and inoperable primary neuroendocrine tumors of rare sites. <i>World Journal of Nuclear Medicine</i> , 2017, 16, 223-228.	0.3	9
85	Quantitative metabolic volumetric product on 18Fluorine-2fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in assessing treatment response to disease-modifying antirheumatic drugs in rheumatoid arthritis: Multiparametric analysis integrating American college of Rheumatology/European League against Rheumatism criteria. <i>World Journal of Nuclear Medicine</i> , 2017, 16, 283-289.	0.3	10
86	Comparative evaluation of iodine-131 metaiodobenzylguanidine and 18-fluorodeoxyglucose positron emission tomography in assessing neural crest tumors: Will they play a complementary role?. <i>South Asian Journal of Cancer</i> , 2017, 06, 031-034.	0.2	3
87	Sarcoidosis presenting with tracheobronchial calcification and nodularity: An unusual case presentation with treatment response assessment by ^{18}F -FDG-PET/CT. <i>Indian Journal of Nuclear Medicine</i> , 2017, 32, 217.	0.1	2
88	Interlesional 'flip-flop' between Ga-DOTATATE and FDG-PET/CT in thyroglobulin-elevated negative iodine scintigraphy (TENIS) syndrome. <i>The National Medical Journal of India</i> , 2017, 30, 48.	0.1	0
89	Synchronous malignancies of thyroglossal duct cyst and thyroid gland. <i>The National Medical Journal of India</i> , 2017, 30, 76-77.	0.1	0
90	^{177}Lu -DOTATATE versus ^{177}Lu -EDTMP versus cocktail/sequential therapy in bone-confined painful metastatic disease in medullary carcinoma of the thyroid and neuroendocrine tumour. <i>Nuclear Medicine Communications</i> , 2016, 37, 100-102.	0.5	6

#	ARTICLE	IF	CITATIONS
91	Observation on enhanced avidity on somatostatin receptor targeted ⁶⁸ Ga-DOTATATE PET-CT following therapy with everolimus and capecitabineâ€“temozolamide. Nuclear Medicine Communications, 2016, 37, 669-671.	0.5	12
92	⁶⁸ Ga DOTATATE PET/CT of Synchronous Meningioma and Prolactinoma. Clinical Nuclear Medicine, 2016, 41, 230-231.	0.7	8
93	PET-Based Personalized Management in Clinical Oncology. PET Clinics, 2016, 11, 203-207.	1.5	34
94	Favorable Response of Metastatic Merkel Cell Carcinoma to Targeted ¹⁷⁷ Lu-DOTATATE Therapy: Will PRRT Evolve to Become an Important Approach in Receptor-Positive Cases?. Journal of Nuclear Medicine Technology, 2016, 44, 85-87.	0.4	33
95	Correlating and Combining Genomic and Proteomic Assessment with In Vivo Molecular Functional Imaging: Will This Be the Future Roadmap for Personalized Cancer Management?. Cancer Biotherapy and Radiopharmaceuticals, 2016, 31, 75-84.	0.7	14
96	PET-Based Molecular Imaging in Designing Personalized Management Strategy in Gastroenteropancreatic Neuroendocrine Tumors. PET Clinics, 2016, 11, 233-241.	1.5	7
97	¹⁸ F-FDG PET/CT Imaging Features of IgG4-Related Pulmonary Inflammatory Pseudotumor at Initial Diagnosis and During Early Treatment Monitoring. Journal of Nuclear Medicine Technology, 2016, 44, 207-209.	0.4	6
98	¹⁷⁷ Lu-DOTATATE PRRT in Recurrent Skull-Base Phosphaturic Mesenchymal Tumor Causing Osteomalacia: A Potential Application of PRRT Beyond Neuroendocrine Tumors. Journal of Nuclear Medicine Technology, 2016, 44, 248-250.	0.4	27
99	Preface. PET Clinics, 2016, 11, xv-xvi.	1.5	0
100	Grouping of Metastatic Thyroid Carcinoma by Molecular Imaging Features to Allow for Individualized Treatment, with Emphasis on the TENIS Syndrome. Journal of Nuclear Medicine Technology, 2016, 44, 184-189.	0.4	3
101	The case for combined chemotherapy-peptide receptor radionuclide therapy (chemo-PRRT) strategy in metastatic neuroendocrine tumor: predicting and looking at the possible case scenarios. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2453-2455.	3.3	9
102	Evolution of Papillary Thyroid Carcinoma into Tall Cell Variant and TENIS Syndrome. Journal of Nuclear Medicine Technology, 2016, 44, 255-258.	0.4	0
103	Rare Occurrence of Hypergastrinemia Due to Thoracic Neuroendocrine Tumor: Detection and Characterization by ⁶⁸ Ga-DOTATATE PET/CT. Journal of Nuclear Medicine Technology, 2016, 44, 203-204.	0.4	1
104	⁶⁸ Ga DOTATATE PET/CT in Differentiated Thyroid Carcinoma With Fibular Metastasis and Mixed Response to Sorafenib. Clinical Nuclear Medicine, 2016, 41, 772-773.	0.7	4
105	¹⁷⁷ Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function. Journal of Nuclear Medicine Technology, 2016, 44, 65-69.	0.4	12
106	¹⁸ F-FDG PET/CT Prediction of an Aggressive Clinical Course for Dermatofibrosarcoma Protuberans. Journal of Nuclear Medicine Technology, 2016, 44, 88-89.	0.4	4
107	Diagnosis of Dual Malignancy by ¹⁸ F-FDG PET/CT in the Setting of Paraneoplastic Cerebellar Degeneration. Journal of Nuclear Medicine Technology, 2016, 44, 52-53.	0.4	2
108	Multimodality molecular imaging (FDG-PET/CT, US elastography, and DWI-MRI) as complimentary adjunct for enhancing diagnostic confidence in reported intermediate risk category thyroid nodules on bethesda thyroid cytopathology reporting system. World Journal of Nuclear Medicine, 2016, 15, 130.	0.3	3

#	ARTICLE	IF	CITATIONS
109	Unusual false positive radioiodine uptake on ¹³¹ I whole body scintigraphy in three unrelated organs with different pathologies in patients of differentiated thyroid carcinoma: A case series. World Journal of Nuclear Medicine, 2016, 15, 137-141.	0.3	8
110	Metastatic neuroendocrine tumor with extensive bone marrow involvement at diagnosis: Evaluation of response and hematological toxicity profile of PRRT with ¹⁷⁷ Lu-DOTATATE. World Journal of Nuclear Medicine, 2016, 15, 38-43.	0.3	25
111	Bilateral axillary and infrahilar nodal metastases in follicular variant of papillary thyroid carcinoma (transformed into poorly differentiated subtype) in the setting of elevated thyroglobulin and negative radioiodine scintigraphy. Journal of Cancer Research and Therapeutics, 2016, 12, 423.	0.3	1
112	Fraction, Cycle, or a New Terminology? What Would Be Most Appropriate for Molecularly Targeted Radiotherapy with Unsealed Sources?. Journal of Nuclear Medicine Technology, 2015, 43, 301-301.	0.4	0
113	Correlation and discordance of tumour proliferation index and molecular imaging characteristics and their implications for treatment decisions and outcome pertaining to peptide receptor radionuclide therapy in patients with advanced neuroendocrine tumour. Nuclear Medicine Communications, 2015, 36, 766-774.	0.5	17
114	Vasodilator stress with adenosine and the gender preponderance for tolerability and manifestation of adverse symptoms: Is there a physiological basis?. Journal of Nuclear Cardiology, 2015, 22, 1158.	1.4	0
115	Ursodeoxycholic acid versus phenobarbital pretreatment prior to hepatobiliary scintigraphy in neonatal cholestasis: is it time for shifting gears towards a practice change?. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1160-1161.	3.3	1
116	Defining a rational step-care algorithm for managing thyroid carcinoma patients with elevated thyroglobulin and negative on radioiodine scintigraphy (TENIS): considerations and challenges towards developing an appropriate roadmap. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1167-1171.	3.3	18
117	¹⁸ -Fluoro-deoxyglucose PET/Computed Tomography in Infection and Aseptic Inflammatory Disorders. PET Clinics, 2015, 10, 431-439.	1.5	5
118	Role of ² -Fluoro-2-Deoxyglucose PET/Computed Tomography in Carcinoma of Unknown Primary. PET Clinics, 2015, 10, 297-310.	1.5	12
119	The current place and indications of ¹³¹ I-metaiodobenzylguanidine therapy in the era of peptide receptor radionuclide therapy. Nuclear Medicine Communications, 2015, 36, 1-7.	0.5	9
120	Late Manifestation of Struma Peritonei and Widespread Functioning Lesions in the Setting of Struma Ovarii Simulating Highly Differentiated Follicular Carcinoma. Journal of Nuclear Medicine Technology, 2015, 43, 231-233.	0.4	15
121	Incidental Diagnosis of an Asymptomatic Hydatid Cyst Through Low-Grade ¹⁸ F-FDG Uptake in the Peripheral Rim. Journal of Nuclear Medicine Technology, 2015, 43, 292-294.	0.4	4
122	Clinical Efficacy and Safety Comparison of ¹⁷⁷ Lu-EDTMP with ¹⁵³ Sm-EDTMP on an Equidose Basis in Patients with Painful Skeletal Metastases. Journal of Nuclear Medicine, 2015, 56, 1513-1519.	2.8	45
123	Assessment of Treatment Response Using PET. PET Clinics, 2015, 10, 9-26.	1.5	17
124	Unusual solitary splenic metastasis from pyriform fossa carcinoma detected by FDG-PET. Indian Journal of Cancer, 2015, 52, 524.	0.2	2
125	Fluro-deoxygenase-positron emission tomography/computed tomography in hard metal lung disease. Lung India, 2015, 32, 480.	0.3	2
126	Emerging clinical applications of PET based molecular imaging in oncology: the promising future potential for evolving personalized cancer care. Indian Journal of Radiology and Imaging, 2015, 25, 332-341.	0.3	24

#	ARTICLE	IF	CITATIONS
127	Thymus uptake of ¹³¹ I in patients with differentiated thyroid carcinoma: Three different case scenarios and patterns of uptake and the importance of its recognition in thyroid cancer practice. <i>Journal of Cancer Research and Therapeutics</i> , 2015, 11, 648.	0.3	6
128	Focal thyroid incidentaloma on whole body fluorodeoxyglucose positron emission tomography/computed tomography in known cancer patients: A case-based discussion with a series of three examples. <i>Journal of Cancer Research and Therapeutics</i> , 2015, 11, 1029.	0.3	0
129	Midline or near-midline radioiodine uptake in the oropharyngeal region in patients of differentiated thyroid carcinoma: Differential diagnosis between lingual thyroid and retropharyngeal nodal metastasis, the subtle clues in the scan and their implications for patient management. <i>South Asian Journal of Cancer</i> , 2015, 04, 098-099.	0.2	0
130	FDG-PET/CT imaging in hyperimmunoglobulin E syndrome. <i>The National Medical Journal of India</i> , 2015, 28, 47.	0.1	0
131	¹⁸ F-FDG PET/CT demonstrating response to targeted therapy in synchronous metastatic adenocarcinoma of the lung and poorly differentiated carcinoma of the thyroid. <i>The National Medical Journal of India</i> , 2015, 28, 155.	0.1	0
132	The Use of ^{99m} Tc-HYNIC-TOC and ¹⁸ F-FDG PET/CT in the Evaluation of Duodenal Neuroendocrine Tumor with Atypical and Extensive Metastasis Responding Dramatically to a Single Fraction of PRRT with ¹⁷⁷ Lu-DOTATATE. <i>Journal of Nuclear Medicine Technology</i> , 2014, 42, 296-298.	0.4	9
133	Supportive Measures and Finer Practice Points in ¹⁷⁷ Lu-DOTATATE PRRT for NET: Aiming for Optimal Disease Management. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1916-1917.	2.8	5
134	Comparative Evaluation of 24-Hour Thyroid ¹³¹ I Uptake Between A Camera-Based Method Using Medium-Energy Collimator and Standard Uptake Probe-Based Method. <i>Journal of Nuclear Medicine Technology</i> , 2014, 42, 194-197.	0.4	8
135	¹⁸ F-FDG PET and PET/CT in Diagnosis and Treatment Monitoring of Pyrexia of Unknown Origin Due to Tuberculosis with Prominent Hepatosplenic Involvement. <i>Journal of Nuclear Medicine Technology</i> , 2014, 42, 235-237.	0.4	11
136	FDG PET for Diagnosing Infection in Hip and Knee Prostheses. <i>Clinical Nuclear Medicine</i> , 2014, 39, 609-615.	0.7	77
137	^{99m} Tc HYNIC-TOC Imaging and ¹⁷⁷ Lu DOTA-Octreotate Treatment in Non- ¹³¹ Iodine-Concentrating Dedifferentiated Thyroid Carcinoma Metastases. <i>Clinical Nuclear Medicine</i> , 2014, 39, 632-634.	0.7	2
138	Regional Lymph node hypermetabolism corresponding to the involved joints on FDG-PET in newly diagnosed patients of rheumatoid arthritis: observation and illustration in symmetrical and asymmetric joint involvement. <i>Rheumatology International</i> , 2014, 34, 413-415.	1.5	10
139	Special Relevance of FDG-PET as an Upfront Diagnostic Modality at Initial Diagnosis and in Suspected Recurrence in Patients of Breast Carcinoma Hailing From Lower Socioeconomic Status Owing to Relative Late Presentation: A Pilot Study in a Medical College Hospital Setting in India. <i>Indian Journal of Surgical Oncology</i> , 2014, 5, 46-58.	0.3	0
140	PET/CT in patients with liver lesions of different nature. <i>Clinical and Translational Imaging</i> , 2014, 2, 139-155.	1.1	8
141	FDG-PET/CT in Infectious and Inflammatory Diseases. <i>PET Clinics</i> , 2014, 9, 497-519.	1.5	59
142	FDG PET/CT methodology for evaluation of treatment response in lymphoma: from a graded visual analysis and a semiquantitative SUV _{max} to global disease burden assessment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2158-2160.	3.3	38
143	Increasing cardiac ¹⁸ F-fluorodeoxyglucose (FDG) uptake on PET-CT as a biomarker for cardiotoxicity of chemo-radiotherapy in cancer: A myth or a reality?. <i>Radiotherapy and Oncology</i> , 2014, 112, 451-452.	0.3	5
144	Employing Bayesian approach to the intermediate risk categories of the Bethesda thyroid cytopathology reporting system: can FDG PET/CT find a strong enough evidence-base to be practised clinically as an adjunct?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2354-2355.	3.3	1

#	ARTICLE	IF	CITATIONS
145	The role of dual and multiple time point imaging of FDG uptake in both normal and disease states. <i>Clinical and Translational Imaging</i> , 2014, 2, 281-293.	1.1	21
146	The Basic Principles of FDG-PET/CT Imaging. <i>PET Clinics</i> , 2014, 9, 355-370.	1.5	84
147	Examining recombinant human TSH primed 131I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1767-1780.	3.3	15
148	Dual tracer imaging approach in assessing tumor biology and heterogeneity in neuroendocrine tumors: its correlation with tumor proliferation index and possible multifaceted implications for personalized clinical management decisions, with focus on PRRT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1492-1496.	3.3	41
149	Adrenal metastasis from differentiated thyroid carcinoma documented on post-therapy 131I scan: A case based discussion. <i>World Journal of Radiology</i> , 2014, 6, 56.	0.5	6
150	Psoas muscle metastasis from cervical carcinoma: Correlation and comparison of diagnostic features on FDG-PET/CT and diffusion-weighted MRI. <i>World Journal of Radiology</i> , 2014, 6, 125.	0.5	13
151	Evaluation of 18F-FDG Uptake Pattern in Brown Adipose Tissue Over Extended Time Period as Assessed by Multiple Time Point 18F-FDG-PET. <i>Nuclear Medicine and Molecular Imaging</i> , 2013, 47, 89-97.	0.6	3
152	Gratifying clinical experience with an indigenously formulated single-vial lyophilized HYNIC-TOC kit at the radiopharmaceutical division of BARC: a pivotal boost for building up a peptide receptor radionuclide therapy programme in an Indian setting. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1622-1624.	3.3	13
153	Striking asymmetry in cerebral metabolism in Dyke-Davidoff-Masson (DDM) syndrome: FDG-PET and MRI correlation. <i>Acta Neurochirurgica</i> , 2013, 155, 519-521.	0.9	3
154	Should Grade of Tracer Uptake on Somatostatin Receptor-Targeted Imaging Be the Major Determinant and Break the Barrier of Histopathologic Criteria for Determining the Suitability of Peptide Receptor Radionuclide Therapy?. <i>Journal of Nuclear Medicine</i> , 2013, 54, 2018.2-2019.	2.8	7
155	The Added Clinical Value of 18F-FDG PET/CT in Evaluating Intratracheal Recurrence of Differentiated Thyroid Carcinoma: Implications for Planning Surgery, Assessing Its Completeness, and Planning Radioiodine Therapy. <i>Journal of Nuclear Medicine Technology</i> , 2013, 41, 302-305.	0.4	1
156	Ring-enhancing brain lesions, clinical presentation of focal seizures, and inconclusive anatomical neuroimaging features. <i>Nuclear Medicine Communications</i> , 2013, 34, 1237-1239.	0.5	1
157	Excellent response to combined radioiodine and enoxaparin in the setting of tumor venous thrombosis from differentiated thyroid carcinoma involving internal jugular and subclavian veins. <i>Future Oncology</i> , 2013, 9, 1813-1818.	1.1	0
158	Positron emission tomography-computed tomography in the management of lung cancer: An update. <i>South Asian Journal of Cancer</i> , 2013, 2, 171.	0.2	23
159	A Logical levothyroxine dose Individualization: Optimization Approach at discharge from Radioiodine therapy ward and during follow-up in patients of Differentiated Thyroid Carcinoma: Balancing the Risk based strategy and the practical issues and challenges: Experience and Views of a large volume referral centre in India. <i>Indian Journal of Nuclear Medicine</i> , 2013, 28, 1.	0.1	1
160	Imaging Calcific Concretions of Pulmonary Alveolar Microlithiasis With PET. <i>Clinical Nuclear Medicine</i> , 2012, 37, 707-708.	0.7	9
161	Unusual Isolated Perineal Recurrence in Mucinous Adenocarcinoma of the Rectum After Abdominoperineal Resection. <i>Clinical Nuclear Medicine</i> , 2012, 37, 989-990.	0.7	2
162	Serendipitous Observation of Hepatic Metastases on 18F-Fluoride PET in a Patient with Infiltrating Ductal Carcinoma of Breast. <i>Clinical Nuclear Medicine</i> , 2012, 37, 1176-1178.	0.7	8

#	ARTICLE	IF	CITATIONS
163	FDG PET and PET/CT Imaging in Complicated Diabetic Foot. PET Clinics, 2012, 7, 151-160.	1.5	16
164	Promising Roles of PET in Management of Arthroplasty-Associated Infection. PET Clinics, 2012, 7, 139-150.	1.5	3
165	Value of 18F NaF PET/CT in the Detection and Global Quantification of Cardiovascular Molecular Calcification as Part of the Atherosclerotic Process. PET Clinics, 2012, 7, 329-339.	1.5	1
166	Adding surgery as a complementary approach to radioiodine therapy in patients of differentiated thyroid carcinoma with large solitary flat bone metastases: the unresolved issues. Journal of Surgical Oncology, 2012, 105, 622-622.	0.8	2
167	Nuclear medicine, scientific publishing and the era of cost containment: what factors hold the key?. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1358-1359.	3.3	0
168	The scope and potentials of functional radionuclide imaging towards advancing personalized medicine in oncology: emphasis on PET-CT. Discovery Medicine, 2012, 13, 65-73.	0.5	15
169	Reverse discordance™ between 68Ga-DOTA-NOC PET/CT and 177Lu-DOTA-TATE posttherapy scan. Nuclear Medicine Communications, 2011, 32, 654-658.	0.5	9
170	[131I]Metaiodobenzylguanidine therapy in neural crest tumors. Nuclear Medicine Communications, 2011, 32, 1201-1210.	0.5	14
171	Active pre-treatment pure pulmonary parenchymal sarcoidosis with raised serum angiotensin converting enzyme level: characteristics on PET with glucose metabolism and cell proliferation tracers and HRCT. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1584-1585.	3.3	4
172	Response to low-dose oral capecitabine monotherapy in an elderly frail patient with metastatic breast carcinoma and impaired renal function: documentation by fluorodeoxyglucose positron emission tomography. Japanese Journal of Radiology, 2011, 29, 291-292.	1.0	0
173	Detection by (18)F-FDG PET of unsuspected extensive bone marrow metastases in a case of basosquamous carcinoma of the cheek. Hellenic Journal of Nuclear Medicine, 2011, 14, 307-8.	0.2	2
174	A pregnant woman with metastatic papillary thyroid carcinoma and paraplegia: Multiple considerations involved in the management. Hellenic Journal of Nuclear Medicine, 2011, 14, 320-1.	0.2	2
175	Unilateral Solitary Breast Metastasis From Medullary Carcinoma of Thyroid Detected by FDG-PET. Clinical Nuclear Medicine, 2010, 35, 512-513.	0.7	3
176	FDG PET in Ruptured Pulmonary Hydatid Cyst. Clinical Nuclear Medicine, 2010, 35, 471-472.	0.7	6
177	PET and PET/CT in gastrointestinal stromal tumours: the unanswered questions and the potential newer applications. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1255-1258.	3.3	9
178	Dose fractionation in 131I-metaiodobenzylguanidine (MIBG) therapy: should the tumour biology and intent of therapy be the guide?. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1798-1799.	3.3	4
179	Personalized versus evidence-based medicine with PET-based imaging. Nature Reviews Clinical Oncology, 2010, 7, 665-668.	12.5	26
180	Fluorodeoxyglucose-positron emission tomography imaging characteristics of unusual cystic metastasis on the liver surface arising from gallbladder carcinoma. Japanese Journal of Radiology, 2009, 27, 194-196.	1.0	1

#	ARTICLE	IF	CITATIONS
181	Metastasis of humeral osteosarcoma to the contralateral breast detected by 99mTc-MDP skeletal scintigraphy. Japanese Journal of Radiology, 2009, 27, 455-457.	1.0	10
182	Selecting the optimal image segmentation strategy in the era of multitracer multimodality imaging: a critical step for image-guided radiation therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 180-181.	3.3	15
183	Early FDG-PET response—adapted risk stratification and further therapeutic decision-making in lymphoma: will this replace the established prognostic indices and be the standard-of-care in clinical management?. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 2089-2090.	3.3	6
184	PET and PET-CT Imaging in Treatment Monitoring of Breast Cancer. PET Clinics, 2009, 4, 359-369.	1.5	2
185	Early Documentation of Therapeutic Response at 6 Weeks Following Corticosteroid Therapy in Extensive Sarcoidosis. Clinical Nuclear Medicine, 2009, 34, 689-690.	0.7	21
186	Unusual Involvement of Scalp and Bilateral Kidneys in an Aggressive Mediastinal Diffuse Large B Cell Lymphoma. Clinical Nuclear Medicine, 2009, 34, 638-641.	0.7	4
187	Bilateral adrenal metastases and metastatic subcutaneous deposit in the chest wall from osteosarcoma of the mandible: utility of 18F-FDG-PET. Hellenic Journal of Nuclear Medicine, 2009, 12, 51-4.	0.2	2
188	Diffuse bone marrow uptake of 99mTc (III) DMSA in Fanconi's anemia. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1402-1402.	3.3	0
189	Functional mapping of pattern and probability of locoregional and distant metastases: can FDG-PET/CT imaging data be the basis for multidimensional scaling in patients with cancer?. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1736-1737.	3.3	0
190	FDG-PET and PET/CT in the clinical management of gastrointestinal stromal tumor. Nuclear Medicine Communications, 2008, 29, 1026-1039.	0.5	36
191	Diffuse Intense FDG Uptake in the Bone Marrow in Gastrointestinal Stromal Tumor With Coexistent Polycythemia Rubra Vera. Clinical Nuclear Medicine, 2008, 33, 782-783.	0.7	6
192	Detection of Unsuspected Metachronous Second Primary Malignancy Giving Rise to Supposed "Non-Iodine Avid Metastasis" in Differentiated Thyroid Carcinoma. Clinical Nuclear Medicine, 2007, 32, 655-658.	0.7	4
193	Intense F-18 FDG Uptake in the Stomach Wall in Follicular Gastritis in Zollinger-Ellison Syndrome. Clinical Nuclear Medicine, 2007, 32, 150-151.	0.7	3
194	Uptake Characteristics of FDG in Multiple Juvenile Cellular Fibroadenomata of the Breast. Clinical Nuclear Medicine, 2007, 32, 203-204.	0.7	9
195	Relapse of cervical cancer presenting as symptoms of Collet-Sicard syndrome with metastatic subcutaneous and adrenal deposits. Lancet Oncology, The, 2006, 7, 610.	5.1	4
196	???Cold??? Vertebrae on F-18 FDG PET: Causes and Characteristics. Clinical Nuclear Medicine, 2006, 31, 445-450.	0.7	12
197	Potential clinical role of FDG-PET in detecting sarcomatous transformation in von Recklinghausen's Disease: a case study and review of the literature. Journal of Neuro-Oncology, 2006, 80, 91-95.	1.4	18
198	Unilateral testicular relapse of abdominal non-Hodgkin lymphoma detected by FDG-PET. Pediatric Radiology, 2006, 36, 274-275.	1.1	2

#	ARTICLE	IF	CITATIONS
199	Avid 18F-FDG uptake in rectal hemorrhoid in a patient with metastatic medullary carcinoma of thyroid. Indian Journal of Gastroenterology, 2006, 25, 257.	0.7	2
200	Unsuspected Metastatic Male Breast Nodule From Synovial Sarcoma Detected by FDG PET. Clinical Nuclear Medicine, 2005, 30, 289-290.	0.7	20
201	18F-FDG uptake in bilateral adrenal hyperplasia causing Cushing's syndrome. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 384-384.	3.3	29
202	¹⁸ F-FDG PET in primary oat cell carcinoma of the esophagus. Indian Journal of Cancer, 2005, 42, 60.	0.2	10
203	Unusually Elevated Liver Radioactivity on F-18 FDG PET in Hodgkin's Disease. Clinical Nuclear Medicine, 2004, 29, 626-628.	0.7	26
204	Unilateral proptosis with thyrotoxicosis resulting from solitary retroorbital soft tissue metastasis from follicular carcinoma thyroid. Clinical Nuclear Medicine, 2001, 26, 136-138.	0.7	15
205	Metastatic Extra-Adrenal Pheochromocytoma with Single Kidney and Renal Compromise: A Case Report of Excellent Response, Tolerability, and Outcome to a Modified Regimen of 131I-mIBG, and Decision-Making between 131I-mIBG Therapy and PRRT. Indian Journal of Medical and Paediatric Oncology, 0, ...	0.1	1